Literature DB >> 7541125

Haemangiomatosis in children: value of MRI during therapy.

B Stöver1, J Laubenberger, C Niemeyer, F Stahl, M Brandis, M Langer.   

Abstract

MRI findings of 18 examinations of six children with haemangiomatosis and one with extended arteriovenous malformation are reported. Structures involved were the liver, liver and lung, periorbital area and the thigh. Response to interferon therapy, in particular, was assessed. With MRI the disease can be characterized and the extent of the lesions and size of the haemangiomas measured. Coronal views provide excellent demonstration of the involved structures in liver and lung haemangiomatosis. Two children showed response to interferon therapy with a reduction in lesion size and subsequently in number. Signal intensity decreased slightly on T2-weighted images. During treatment, however, no definitive fibrotic zones were seen. Following complete regression, signal intensity of the liver parenchyma was homogeneous in both weightings, that is, no fibrotic areas were visible 18 months after the beginning of treatment. Two children showed no response and one child died from congestive cardiac failure. The periorbital haemangioma was reduced in size and the lesion in the thigh might be classified as an arteriovenous malformation. In children MRI can replace CT as it is a reliable imaging modality for diagnosing haemangiomatosis and monitoring therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541125     DOI: 10.1007/bf02010325

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  11 in total

1.  Biological classification of soft-tissue vascular anomalies: MR correlation.

Authors:  J S Meyer; F A Hoffer; P D Barnes; J B Mulliken
Journal:  AJR Am J Roentgenol       Date:  1991-09       Impact factor: 3.959

2.  MRI of disseminated neonatal hemangiomatosis: case report.

Authors:  S P Montgomery; A P Guillot; R A Barth
Journal:  Pediatr Radiol       Date:  1990

3.  Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.

Authors:  F X Real; H F Oettgen; S E Krown
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

4.  RARE imaging: a fast imaging method for clinical MR.

Authors:  J Hennig; A Nauerth; H Friedburg
Journal:  Magn Reson Med       Date:  1986-12       Impact factor: 4.668

5.  Musculoskeletal haemangiomas: comparison of MRI with CT.

Authors:  J M Hawnaur; R W Whitehouse; J P Jenkins; I Isherwood
Journal:  Skeletal Radiol       Date:  1990       Impact factor: 2.199

6.  Infantile hepatic hemangiomas. Clinical features, radiologic investigations, and treatment of 20 patients.

Authors:  P Stanley; G D Geer; J H Miller; V Gilsanz; B H Landing; I M Boechat
Journal:  Cancer       Date:  1989-08-15       Impact factor: 6.860

7.  Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics.

Authors:  J B Mulliken; J Glowacki
Journal:  Plast Reconstr Surg       Date:  1982-03       Impact factor: 4.730

8.  Distinction of hepatic cavernous hemangioma from hepatic metastases with MR imaging.

Authors:  K C Li; G M Glazer; L E Quint; I R Francis; A M Aisen; W D Ensminger; F L Bookstein
Journal:  Radiology       Date:  1988-11       Impact factor: 11.105

9.  Hemangiomas and vascular malformations of the head and neck: MR characterization.

Authors:  L L Baker; W P Dillon; G B Hieshima; C F Dowd; I J Frieden
Journal:  AJNR Am J Neuroradiol       Date:  1993 Mar-Apr       Impact factor: 3.825

10.  Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon.

Authors:  A Rios; P W Mansell; G R Newell; J M Reuben; E M Hersh; J U Gutterman
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

View more
  1 in total

1.  MR imaging of hepatic hemangiomas of infancy and changes seen with interferon alpha-2a treatment.

Authors:  T Chung; F A Hoffer; P E Burrows; H J Paltiel
Journal:  Pediatr Radiol       Date:  1996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.